Immunocore (IMCR) and the European Organization for Research and Treatment of Cancer said Wednesday that they enrolled the first patient in the phase 3 trial of tebentafusp as adjuvant treatment for uveal melanoma.

The study led by the EORTC will test to see if tebentafusp can stop or slow down the relapse of this type of eye cancer in patients at high risk of recurrence, according to a joint statement. The trial is anticipated to enroll 290 patients with uveal melanoma who have undergone surgery or radiotherapy, according to the statement.

Tebentafusp, sold under the brand name Kimmtrak, is approved in 38 countries to treat unresectable or metastatic uveal melanoma.

Shares of Immunocore were down 1.5% in recent trading.